# EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)

> **NCT04335032** · PHASE3 · UNKNOWN · sponsor: **S.L.A. Pharma AG** · enrollment: 284 (estimated)

## Conditions studied

- SARS-CoV-2

## Interventions

- **DRUG:** Eicosapentaenoic acid gastro-resistant capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04335032
- **Lead sponsor:** S.L.A. Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-08
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-12-01
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335032, "EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04335032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*